The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The comparative efficacy and toxicity of second‐line drugs in rheumatoid arthritis results of two metaanalyses
Abstract
We performed 2 metaanalyses of placebo‐controlled and comparative clinical trials to examine the relative efficacy and toxicity of methotrexate (MTX), injectable gold, D‐penicillamine (DP), sulfasalazine (SSZ), auranofin (AUR), and antimalarial drugs, the second‐line drugs most commonly used to treat rheumatoid arthritis (RA). For the efficacy study, we applied a set of inclusion criteria and focused on trials which provided information on tender joint count, erythrocyte sedimentation rate, or grip strength. We found 66 clinical trials that contained 117 treatment groups of interest, and for each drug, we combined the treatment groups. For each outcome, results showed that AUR tended to be weaker than other second‐line drugs. The results of the 3 outcome measures were synthesized into a composite measure of outcomes, and AUR was significantly weaker than MTX (P = 0.006), injectable gold (P < 0.0001), DP (P < 0.0001), and SSZ (P = 0.009) and was slightly, but not significantly, weaker than antimalarial agents (P = 0.11). We also found heterogeneity among antimalarial agents, in that patients treated with chloroquine did better than those treated with hydroxychloroquine. We found little difference in efficacy between MTX, injectable gold, DP, and SSZ. A power analysis showed that a trial should contain at least 170 patients per treatment group to successfully differentiate between more effective and less effective (e.g., AUR) second‐line drugs. None of the reported interdrug comparative trials we reviewed were this large. For the toxicity study, our inclusion criteria captured RA trials which reported the proportion of patients who discontinued therapy because of drug toxicity and the total proportion who dropped out. We found 71 clinical trials that contained 129 treatment groups. The average proportion who dropped out and the average proportion who dropped out because of drug toxicity were computed for each drug. Overall, 30.2% of the patients in these trials dropped out; 50% of them did so because of drug toxicity. Injectable gold had higher toxicity rates (P < 0.05) and higher total dropout rates (P < 0.01) than any other drug; 30% of goldtreated patients dropped out because of side effects versus 15% of all trial patients. Antimalarial drugs and AUR had relatively low rates of toxicity; the rate for MTX was imprecise because of discrepancies between trials. Thus, of the commonly used second‐line drugs, AUR is the weakest, and injectable gold is the most toxic. Agents introduced in the future will be compared with these drugs. If a curative drug is not found, large multicenter trials or data synthesis from multiple drug trials may be necessary to identify new treatment regimens that have promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
revision of diagnostic criteria for rheumatoid arthritis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-47 · Cited by 2,237
1958 Revision of diagnostic criteria for rheumatoid arthritis
Ropes, M. W., Bennett, G. A., Cobb, S., Jacox, R., & Jessar, R. A. (1959) · Arthritis & Rheumatism · doi:10.1002/1529-0131(195902)2:1<16::aid-art1780020104>3.0.co;2-9 · Cited by 1,999
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355
(1968) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067150 · Cited by 1,349
The transformation of poisson, binomial and negative-binomial data
ANSCOMBE, F. J. (1948) · Biometrika · doi:10.1093/biomet/35.3-4.246 · Cited by 1,300
Meta-Analyses of Randomized Controlled Trials
Sacks, H. S., Berrier, J., Reitman, D., Ancona-Berk, V. A., & Chalmers, T. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702193160806 · Cited by 1,250
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872
Reporting on Methods in Clinical Trials
DerSimonian, R., Charette, L. J., McPeek, B., & Mosteller, F. (1982) · New England Journal of Medicine · doi:10.1056/nejm198206033062204 · Cited by 499
Williams, H. J., Willkens, R. F., Samuelson, C. O., Alarcón, G. S., Guttadauria, M., Yarboro, C., Polisson, R. P., Weiner, S. R., Luggen, M. E., Billingsley, L. M., et al. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280702 · Cited by 462
Bombardier, C., Ware, J., Russell, I. J., Larson, M., Chalmers, A., Read, J. L., Arnold, W., Bennett, R., Caldwell, J., Hench, P. K., et al. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90539-5 · Cited by 359
ANDERSEN, P. A., WEST, S. G., O'DELL, J. R., VIA, C. S., CLAYPOOL, R. G., & KOTZIN, B. L. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-489 · Cited by 331
Gold Salts in the Treatment of Rheumatoid Arthritis: A Double-Blind Study
SIGLER, J. W., BLUHM, G. B., DUNCAN, H., SHARP, J. T., ENSIGN, D. C., & MCCRUM, W. R. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-1-21 · Cited by 291
CONTROLLED TRIAL OF D(-)PENICILLAMINE IN SEVERE RHEUMATOID ARTHRITIS
Multicentre Trial Group (1973) · The Lancet · doi:10.1016/s0140-6736(73)91536-5 · Cited by 271
Outcome assessment in clinical trials evidence for the sensitivity of a health status measure
Meenan, R. F., Anderson, J. J., Kazis, L. E., Egger, M. J., Altz‐Smith, M., Samuelson, C. O., Willkens, R. F., Solsky, M. A., Hayes, S. P., Blocka, K. L., et al. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780271204 · Cited by 247
Self-citationSample size requirements for evaluating a conservative therapy.
Makuch, R., & Simon, R. M. (1978) · PubMed · Cited by 228
Ward, J. R., James Williams, H., Egger, M. J., Reading, J. C., Boyce, E., Altz‐Smith, M., Samuelson, C. O., Willkens, R. F., Solsky, M. A., Hayes, S. P., et al. (1983) · Arthritis & Rheumatism · doi:10.1002/art.1780261102 · Cited by 195
Self-citationFürst, D. E., Koehnke, R., Burmeister, L. F., et al. (1989) · PubMed · Cited by 179
Which traditional measures should be used in rheumatoid arthritis clinical trials?
Anderson, J. J., Felson, D. T., Meenan, R. F., & Williams, H. J. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320907 · Cited by 138
Self-citationChloroquine in Rheumatoid Arthritis
Freedman, A., & Steinberg, V. L. (1960) · Annals of the Rheumatic Diseases · doi:10.1136/ard.19.3.243 · Cited by 123
Chloroquine Diphosphate in Rheumatoid Arthritis
Popert, A. J., Meijers, K. A. E., Sharp, J., & Bier, F. (1961) · Annals of the Rheumatic Diseases · doi:10.1136/ard.20.1.18 · Cited by 122
Repeatability and objectivity of various measurements in rheumatoid arthritis. A comparative study
Eberl, D. R., Fasching, V., Rahlfs, V. W., et al. (1976) · Arthritis & Rheumatism · doi:10.1002/art.1780190608 · Cited by 109
Hamdy, H., McKendry, R. J. R., Mierins, E., & Liver, J. A. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300401 · Cited by 103
Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.
HUSKISSON, E. C., Gibson, T., Balme, H., Berry, H., BURRY, H. C., Grahame, R., Hart, F. D., Henderson, D., & Wojtulewski, J. A. (1974) · Annals of the Rheumatic Diseases · doi:10.1136/ard.33.6.532 · Cited by 93
A toxicity index for comparison of side effects among different drugs
Fries, J. F., Spitz, P. W., Williams, C. A., Bloch, D. A., Singh, G., & Hubert, H. B. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330117 · Cited by 91
Low‐Dose D‐Penicillamine Therapy in Rheumatoid Arthritis
Williams, H. J., Ward, J. R., Reading, J. C., Egger, M. J., Grandone, J. T., Samuelson, C. O., Furst, D. E., Sullivan, J. M., Watson, M. A., Guttadauria, M., et al. (1983) · Arthritis & Rheumatism · doi:10.1002/art.1780260502 · Cited by 88
Hydroxychloroquine sulfate (“Plaquenil”) in treatment of rheumatoid arthritis
Hamilton, E. B. D., & Scott, J. T. (1962) · Arthritis & Rheumatism · doi:10.1002/art.1780050507 · Cited by 80
Antimalarial drugs for rheumatoid arthritis
Mackenzie, A. H. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90474-6 · Cited by 73
Chloroquine and Rheumatoid Arthritis
Freedman, A. (1956) · Annals of the Rheumatic Diseases · doi:10.1136/ard.15.3.251 · Cited by 71
Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials
Felson, D. T., Anderson, J. J., & Meenan, R. F. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330119 · Cited by 49
Self-citation
Cited by
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Self-citationBucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Guidelines for the management of rheumatoid arthritis: 2002 Update
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) · Arthritis & Rheumatism · doi:10.1002/art.10148 · Cited by 1,185
Metadata
- Authors
- Felson, D. T., Anderson, J. J., & Meenan, R. F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1990-10
- Volume
- 33
- Issue
- 10
- Pages
- 1449-1461
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2006549880
- Cited by
- 470
- References
- 30
- FWCI
- 16.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.